Because the activation of PBK/TOPK signaling pathway is closely related to the occurrence, development, and biological behavior of lung cancer and targeting PBK/TOPK can affect the chemotherapy of lung cancer [42–44], our findings provided a better therapy or enhanced the efficacy of chemoradiotherapy for lung cancer by targeting PBK/TOPK with baicalin. This evidence concerns the gene PBK and lung carcinoma.